Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Iberdomide Approval Elevates MRD's Role in Myeloma: Prerna Mewawalla, MD

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 14 August 2026 · Fusion42 review

The FDA approval of iberdomide for multiple myeloma elevates the role of minimal residual disease (MRD) testing in treatment decisions and patient monitoring.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA's nod on iberdomide boosts MRD testing's significance in myeloma care, creating a new pathway for therapies and diagnostics in biotech. You in biotech or diagnostics must now align product development and clinical strategies with MRD-driven endpoints.

◆ Coverage

1 source · 14 Aug 2026

◆ Related on Wire

◆ Topics

Biotechiberdomidemultiple-myelomamrd-testingdrug-approvaloncology